Loxoprofen (sodium)

Loxoprofen sodium is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen sodium can reduce atherosclerosis and shows antitumor activity[1][2][3][4].

Product Specifications

CAS Number

[80382-23-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/loxoprofen-sodium.html

Purity

99.63

Solubility

DMSO : 19.23 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

O=C1C(CCC1)CC2=CC=C(C(C)C(O[Na])=O)C=C2

Molecular Formula

C15H17NaO3

Molecular Weight

268.28

Precautions

H302, H315, H319, H335

References & Citations

[1]Riendeau D, et al. Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg Med Chem Lett. 2004;14 (5) :1201-1203.|[2]Paudel S, et al. Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators. Pharmaceutics. 2019;11 (9) :479. Published 2019 Sep 16.|[3]Hamaguchi M, et al. Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation. J Clin Biochem Nutr. 2010 Sep;47 (2) :138-47.|[4]Kanda A, et al. Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor. Acta Oncol. 2003;42 (1) :62-70.